What is he best known for?
The fields of study he is best known for:
Klaus Elenius focuses on Cancer research, Cell biology, ERBB4, Gene isoform and Epidermal growth factor.
His studies in Cancer research integrate themes in fields like Cancer, Breast cancer, Trastuzumab, ErbB and Gefitinib.
His Cancer study incorporates themes from Stomach, Chromogenic in situ hybridization and CISH.
ERBB4 is a primary field of his research addressed under Signal transduction.
His Epidermal growth factor research is multidisciplinary, incorporating elements of Molecular biology and Tyrosine phosphorylation.
Klaus Elenius interconnects Receptor tyrosine kinase and Binding site in the investigation of issues within Tyrosine phosphorylation.
His most cited work include:
- Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab (544 citations)
- Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab (544 citations)
- ACTIVATION OF HER4 BY HEPARIN-BINDING EGF-LIKE GROWTH FACTOR STIMULATES CHEMOTAXIS BUT NOT PROLIFERATION (327 citations)
What are the main themes of his work throughout his whole career to date?
Klaus Elenius spends much of his time researching Cancer research, Receptor tyrosine kinase, Cell biology, ERBB4 and ErbB.
The concepts of his Cancer research study are interwoven with issues in Cancer, Breast cancer, ERBB3, Epidermal growth factor receptor and Cell growth.
His study in Cancer is interdisciplinary in nature, drawing from both Mutation and Chromogenic in situ hybridization.
His Receptor tyrosine kinase research incorporates themes from Molecular biology and Kinase activity.
His research in Cell biology intersects with topics in Syndecan 1, Endocrinology, Internal medicine, Angiogenesis and Ectodomain.
His ERBB4 study integrates concerns from other disciplines, such as Tyrosine kinase, Neuregulin and Gene isoform.
He most often published in these fields:
- Cancer research (68.48%)
- Receptor tyrosine kinase (62.42%)
- Cell biology (50.30%)
What were the highlights of his more recent work (between 2017-2021)?
- Receptor tyrosine kinase (62.42%)
- Cell biology (50.30%)
- Cancer research (68.48%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Receptor tyrosine kinase, Cell biology, Cancer research, ErbB and Epidermal growth factor receptor.
His work deals with themes such as Gene expression, Downregulation and upregulation, Afatinib, Somatic evolution in cancer and Guanine Nucleotide Exchange Factor VAV3, which intersect with Receptor tyrosine kinase.
His studies deal with areas such as Muscle hypertrophy and VEGF receptors as well as Cell biology.
The study incorporates disciplines such as Blot, ROR1, Carcinoma, Phosphorylation and Extracellular matrix in addition to Cancer research.
In his study, Ubiquitin ligase, Cancer and In situ hybridization is inextricably linked to Cell culture, which falls within the broad field of ErbB.
His Mutation research is multidisciplinary, incorporating perspectives in Jaw neoplasm and Signal transduction.
Between 2017 and 2021, his most popular works were:
- Endothelial Cells Regulate Physiological Cardiomyocyte Growth via VEGFR2-Mediated Paracrine Signaling (34 citations)
- Endothelial Cells Regulate Physiological Cardiomyocyte Growth via VEGFR2-Mediated Paracrine Signaling (34 citations)
- Endothelial Cells Regulate Physiological Cardiomyocyte Growth via VEGFR2-Mediated Paracrine Signaling (34 citations)
In his most recent research, the most cited papers focused on:
Cell biology, Receptor tyrosine kinase, Tyrosine kinase, Mutation and Cancer research are his primary areas of study.
Klaus Elenius has researched Cell biology in several fields, including Muscle hypertrophy, Receptor, Paracrine signalling and VEGF receptors.
His Receptor tyrosine kinase research incorporates elements of Regulated Intramembrane Proteolysis, Ectodomain, Proteasome, Gamma secretase and Transmembrane domain.
He frequently studies issues relating to Cleavage and Tyrosine kinase.
His Mutation study combines topics from a wide range of disciplines, such as EGFR Exon 19 Deletion Mutation, Epidermal growth factor receptor, Kinase, Kinase activity and Protein kinase domain.
He combines subjects such as Cetuximab, EGFR Antibody, Chemotherapy, Oxaliplatin and KRAS with his study of Cancer research.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
